Aviado · Research
Longevity Daily
Tuesday, November 10, 2026
Listen
Today's Brief
Two rapamycin stories published within 24 hours tell different — but not contradictory — tales: a sweeping review of human data finds no survival benefit for the most hyped longevity drug on the market, while a separate study suggests low-dose rapamycin may improve cerebral blood flow in people at genetic Alzheimer's risk. GLP-1 drugs continue their cognitive expansion, with a Science review now linking them to memory protection and reduced neurodegeneration. A surprising small Finnish trial rounds out the cognitive section — 30 minutes on a vibrating mattress combined with blood pressure medication may help clear Alzheimer's-linked proteins from the brain — while Aviado unpacks biotin's overlooked role in controlling whether your body burns fat or stores it.
10 stories4 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
GLP-1 Weight-Loss Drugs Show Surprising Promise for Memory Protection and Brain Aging
A review published in Science finds that GLP-1 receptor agonists — widely used for obesity and diabetes — may also protect the brain against cognitive decline by preserving memory and slowing neurodegeneration. Researchers outline mechanisms linking the drugs to reduced neuroinflammation and improved metabolic signaling in neural tissue, pointing toward potential treatment strategies well beyond weight loss. For the growing number of people already taking semaglutide or tirzepatide, this cognitive protection signal is a meaningful secondary benefit that researchers are now working to formalize.
Read more →Water Fluoridation Does Not Impair Brain Function, Large Irish Study Confirms
A population-based study from Trinity College Dublin tracked 2,495 older adults against 60-plus years of Irish water fluoride records and found zero association between lifetime fluoride exposure and cognitive decline or dementia risk. Participants were divided into low, moderate, and high-exposure groups based on residential histories dating back to 1964 — and cognitive test scores showed no significant differences across any group. Published in the Journal of Dental Research, this is one of the most rigorous human studies on the question and provides strong reassurance for anyone concerned about tap water's effect on the aging brain.
Read more →30 Minutes on a Vibrating Mattress Plus Blood Pressure Medication Cleared Alzheimer's-Linked Brain Proteins in Small Trial
A small pilot trial from the University of Oulu tested whether combining whole-body vibration with blood pressure-lowering medication could enhance the brain's glymphatic system — the overnight waste-clearance mechanism that removes toxic proteins including those linked to Alzheimer's disease. Biomedical engineer Johanna Tuunanen reported that harmful proteins were cleared from the brain 'more efficiently than usual' in the combined intervention group. The sample is small and the work is early-stage, but the non-invasive nature of this approach makes it a compelling avenue for Alzheimer's prevention research if the signal holds in larger trials.
Read more →Supplements & Compounds
STAMINA Trial: A Daily Multi-Ingredient Supplement Significantly Improved Vascular Aging Markers Within Six Months
The STAMINA trial tested a daily multi-ingredient nutritional supplement in healthy adults aged 40 and older and found significant improvements across multiple vascular aging markers — including better endothelial function, reduced arterial stiffness, and lower systolic blood pressure — all within six months. Published in European Heart Journal Open, the results support a multi-target strategy for vascular aging rather than relying on individual compounds in isolation. The trial was randomized and placebo-controlled, lending real credibility to the findings, though the sample was small and larger replication studies are needed before drawing firm conclusions.
Read more →How Biotin Activates the Enzymes That Decide Whether Your Body Burns Fat or Stores It
Biotin's reputation for hair and nails dramatically undersells what it actually does: it activates the five carboxylase enzymes that govern fat synthesis, glucose production, and amino acid metabolism at the cellular level. Meta-analyses show that supplementation at 5–10 mg per day reduces triglycerides by 0.59 mmol/L and fasting glucose by 1.21 mmol/L — meaningful improvements seen even in people without clinical deficiency. Aviado's full analysis walks through the enzyme-level mechanisms and what this means practically for anyone managing elevated triglycerides or blood sugar.
Read the full Aviado analysis →Research & Papers
A Decade of Human Data on Rapamycin Finds No Survival Benefit — The Evidence Is Thinner Than You Think
Rapamycin is the most talked-about longevity drug among biohackers and physicians, but a careful review of a decade of human data — covering roughly 11,000 participants — finds no demonstrated lifespan or healthspan benefit. The only positive signal in humans was a modest improvement in influenza vaccine response; a year-long trial in healthy adults missed its primary endpoint, and its authors had disclosed financial ties to the drug's manufacturer. The picture that emerges isn't that rapamycin is useless, but that the human evidence for its core longevity promise simply does not yet exist — a critical distinction for anyone self-prescribing. If you're currently taking rapamycin for longevity, this analysis is essential reading before your next dose.
Read more →GLP-1 Drugs May Add Roughly Two Years to Lifespan — But the Real Story Is in the Proteins
Biohacker influencers have been claiming GLP-1 drugs dramatically extend lifespan, and mouse data adds some plausibility — but researchers at the 2026 ARDD conference are tempering expectations significantly. Proteomic aging clocks show measurable improvements in people taking GLP-1 drugs, but researcher Roed noted the resulting predicted difference in lifespan may be only about two years. Alex Zhavoronkov and others argue the more important signal is what GLP-1s do to inflammatory and metabolic plasma proteins over time, making proteomic clocks the key surrogate endpoint to watch in ongoing trials.
Read more →Low-Dose Rapamycin May Improve Brain Blood Flow in People at Genetic Risk for Alzheimer's
A new study suggests low-dose rapamycin could improve cerebral blood flow in individuals carrying the APOE4 gene — the strongest known genetic risk factor for Alzheimer's disease. Reduced cerebral perfusion is an early and measurable marker of neurodegeneration, and this finding adds a brain-specific rationale for the drug that sits apart from its contested lifespan effects. Read alongside today's must-read on rapamycin's absent survival data, the emerging picture is nuanced: rapamycin's effects may be highly context- and organ-specific rather than uniformly beneficial or null.
Read more →Lifestyle & Nutrition
Japan's Longevity Industry Is Betting on the Gut Microbiome to Slow Biological Aging
Japanese companies including Morinaga Milk are completing clinical trials on whether probiotic-containing yogurt can measurably slow biological aging — moving gut microbiome research firmly into longevity territory beyond traditional digestive health metrics. The NutraIngredients report also highlights growing interest in autophagy-linked product certifications in Japan, a category blending functional food science with aging biology. This signals where the global longevity nutrition market is heading: toward biomarker-defined aging outcomes rather than broad wellness claims.
Read more →Industry & Policy
American Heart Association Launches National Center for the Brain to Formalize the Heart-Cognitive Health Link
The American Heart Association has announced the AHA Center for the Brain, a national initiative to study how cardiovascular health shapes cognitive aging and dementia risk — and to translate that research into prevention at scale. The center targets the well-established but clinically underutilized connection between heart disease risk factors (hypertension, diabetes, inflammation) and Alzheimer's risk. No budget has been disclosed, but the AHA's institutional weight and reach make this a potential driver of large-scale research funding and eventual clinical guidelines.
Read more →